NICM
KYMR icon

Neo Ivy Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Neo Ivy Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
+27,033
New +$2.14M 0.59% 63
2025
Q4 		– Sell
-19,660
Closed -$1.11M – 448
2025
Q3 		$1.11M Sell
19,660
-839
-4% -$37.8K 0.27% 130
2025
Q2 		$895K Buy
20,499
+6,079
+42% +$209K 0.29% 129
2025
Q1 		$395K Buy
+14,420
New +$526K 0.13% 208

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Neo Ivy Capital Management's KYMR Position: Q1 2026 in Review

Neo Ivy Capital Management opened a new position in Kymera Therapeutics (KYMR) in Q1 2026: 27,033 shares worth $2.25M. The stake represents 0.59% of the portfolio and ranks #63 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in KYMR as recently as Q3 2025.

Neo Ivy Capital Management first reported a position in KYMR in Q1 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Neo Ivy Capital Management held 27,033 shares of Kymera Therapeutics worth $2.25M as of Q1 2026.
  • Kymera Therapeutics was a new Neo Ivy Capital Management position in Q1 2026.
  • Kymera Therapeutics made up 0.59% of Neo Ivy Capital Management's portfolio in Q1 2026, its #63 holding.
  • Neo Ivy Capital Management first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.